--- title: "Aspen Neuroscience tumbles 8% in post-IPO pullback" type: "News" locale: "en" url: "https://longbridge.com/en/news/304516683.md" description: "Aspen Neuroscience fell 8.15% to $11.72 after its amended charter took effect at the IPO close, raising about $140.6 million." datetime: "2026-11-05T19:30:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/304516683.md) - [en](https://longbridge.com/en/news/304516683.md) - [zh-HK](https://longbridge.com/zh-HK/news/304516683.md) generator: "portal-rs" --- # Aspen Neuroscience tumbles 8% in post-IPO pullback Aspen Neuroscience (ASPE.US) tumbled more than **8%** during regular trading to **$11.72**. The company's amended charter took effect on Nov. 2, 2026, coinciding with the close of its initial public offering. Aspen Neuroscience issued **9,375,000** shares of common stock at **$15** per share, raising approximately **$140.6 million** before underwriting discounts and expenses. Based on public media reports. AI-generated; not investment advice. ### Related Stocks - [ASPE.US](https://longbridge.com/en/quote/ASPE.US.md) ## Related News & Research - [ARCH Venture Partners X Discloses 12.9% Stake in Aspen Neuroscience](https://longbridge.com/en/news/304929595.md) - [Aspen Neuroscience's Amended Bylaws Take Effect at IPO Closing](https://longbridge.com/en/news/304014788.md) - [OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake](https://longbridge.com/en/news/304700413.md) - [BUZZ-Street View: Nvidia's AI story intact despite uncertainty at top](https://longbridge.com/en/news/305945171.md) - [OrbiMed Advisors reports acquisition of $15 million in Aspen Neuroscience common shares](https://longbridge.com/en/news/304354913.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**